VYNE Earnings VYNE Therapeutics Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–23 of 23
| Q1 2026 | 2026-03-31 | -0.08 | 2026-05-15 | 10-Q |
| FY 2025 | 2025-12-31 | -0.62 | 2026-02-27 | 10-K |
| Q2 2025 | 2025-06-30 | -0.34 | 2025-08-14 | 10-Q |
| Q1 2026 | 2025-03-31 | -0.20 | 2026-05-15 | 10-Q |
| FY 2025 | 2024-12-31 | -0.93 | 2026-02-27 | 10-K |
| Q3 2024 | 2024-09-30 | -0.65 | 2024-11-07 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.37 | 2025-08-14 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.15 | 2025-05-08 | 10-Q |
| FY 2024 | 2023-12-31 | -2.78 | 2025-03-06 | 10-K |
| Q3 2024 | 2023-09-30 | -6.82 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -4.82 | 2024-08-14 | 10-Q |
| Q1 2024 | 2023-03-31 | -1.74 | 2024-05-09 | 10-Q |
| FY 2023 | 2022-12-31 | -7.28 | 2024-03-01 | 10-K |
| Q3 2023 | 2022-09-30 | -4.18 | 2023-11-13 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.21 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | 1.51 | 2023-05-11 | 10-Q |
| FY 2022 | 2021-12-31 | -25.64 | 2023-03-14 | 10-K |
| Q3 2022 | 2021-09-30 | -1.22 | 2022-11-14 | 10-Q |
| Q2 2022 | 2021-06-30 | -0.81 | 2022-08-12 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.42 | 2022-05-12 | 10-Q |
| FY 2021 | 2020-12-31 | 7.88 | 2022-03-17 | 10-K |
| Q3 2021 | 2020-09-30 | -7.98 | 2021-11-10 | 10-Q |
| Q2 2021 | 2020-06-30 | -9.17 | 2021-08-12 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.